|
[1] ANSTEE QM,REEVES HL,KOTSILITI E,et al. From NASH to HCC:Current concepts and future challenges[J]. Nat Rev Gastroenterol Hepatol,2019,16(7):411-428.
|
|
[2] LEUNG C,YEOH SW,PATRICK D,et al. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic nonalcoholic fatty liver disease[J]. World J Gastroenterol,2015,21(4):1189-1196.
|
|
[3] YOUNOSSI ZM,KOENIG AB,ABDELATIF D,et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes[J]. Hepatology,2016,64(1):73-84.
|
|
[4] KAWAMURA Y,ARASE Y,IKEDA K,et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma[J]. Am J Gastroenterol,2012,107(2):253-261.
|
|
[5] BENGTSSON B,STL P,WAHLIN S,et al. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis[J]. Liver Int,2019,39(6):1098-1108.
|
|
[6] LIU Y,LIU L,ZHOU Y,et al. CKLF1 enhances inflammationmediated carcinogenesis and prevents doxorubicin-induced apoptosis via IL6/STAT3 signaling in HCC[J]. Clin Cancer Res,2019,25(13):4141-4154.
|
|
[7] SHARMA D,WANG J,FU PP,et al. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis[J]. Hepatology,2010,52(5):1713-1722.
|
|
[8] DALAMAGA M,DIAKOPOULOS KN,MANTZOROS CS. The role of adiponectin in cancer:A review of current evidence[J]. Endocr Rev,2012,33(4):547-594.
|
|
[9] HILL-BASKIN AE,MARKIEWSKI MM,BUCHNER DA,et al.Diet-induced hepatocellular carcinoma in genetically predisposed mice[J]. Hum Mol Genet,2009,18(16):2975-2988.
|
|
[10] SHEN J,TSOI H,LIANG Q,et al. Oncogenic mutations and dysregulated pathways in obesity-associated hepatocellular carcinoma[J]. Oncogene,2016,35(49):6271-6280.
|
|
[11] LUO Y,TIAN G,ZHUANG Z,et al. Berberine prevents nonalcoholic steatohepatitis-derived hepatocellular carcinoma by inhibiting inflammation and angiogenesis in mice[J]. Am J Transl Res,2019,11(5):2668-2682.
|
|
[12] GRETEN TF,EGGERT T. Cellular senescence associated immune responses in liver cancer[J]. Hepat Oncol,2017,4(4):123-127.
|
|
[13] HIGHFILL SL,CUI Y,GILES AJ,et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy[J]. Sci Transl Med,2014,6(237):237ra67.
|
|
[14] TAVAZOIE MF,POLLACK I,TANQUECO R,et al. LXR/ApoE activation restricts innate immune suppression in cancer[J].Cell,2018,172(4):825-840. e18.
|
|
[15] ZHENG J,CAI J,LI H,et al. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as prognostic predictors for hepatocellular carcinoma patients with various treatments:A Meta-analysis and systematic review[J]. Cell Physiol Biochem,2017,44(3):967-981.
|
|
[16] van der WINDT DJ,SUD V,ZHANG H,et al. Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis[J].Hepatology,2018,68(4):1347-1360.
|
|
[17] BIJNEN M,JOSEFS T,CUIJPERS I,et al. Adipose tissue macrophages induce hepatic neutrophil recruitment and macrophage accumulation in mice[J]. Gut,2018,67(7):1317-1327.
|
|
[18] YE D,YANG K,ZANG S,et al. Lipocalin-2 mediates nonalcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2[J]. J Hepatol,2016,65(5):988-997.
|
|
[19] CHEN J,LIANG B,BIAN D,et al. Knockout of neutrophil elastase protects against western diet induced nonalcoholic steatohepatitis in mice by regulating hepatic ceramides metabolism[J]. Biochem Biophys Res Commun,2019,518(4):691-697.
|
|
[20] PUIG T,TURRADO C,BENHAMU'B,et al. Novel inhibitors of fatty acid synthase with anticancer activity[J]. Clin Cancer Res,2009,15(24):7608-7615.
|
|
[21] BELORIBI-DJEFAFLIA S,VASSEUR S,GUILLAUMOND F.Lipid metabolic reprogramming in cancer cells[J]. Oncogenesis,2016,5:e189.
|
|
[22] IWAMOTO H,ABE M,YANG Y,et al. Cancer lipid metabolism confers antiangiogenic drug resistance[J]. Cell Metab,2018,28(1):104-117. e5.
|
|
[23] JHO D,BABCOCK TA,HELTON WS,et al. Omega-3 fatty acids:Implications for the treatment of tumor-associated inflammation[J]. Am Surg,2003,69(1):32-36.
|
|
[24] LU X,ZHANG X,ZHANG Y,et al. Metabolic profiling analysis upon acylcarnitines in tissues of hepatocellular carcinoma revealed the inhibited carnitine shuttle system caused by the downregulated carnitine palmitoyltransferase 2[J]. Mol Carcinog,2019,58(5):749-759.
|
|
[25] FUJIWARA N,NAKAGAWA H,ENOOKU K,et al. CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity[J]. Gut,2018,67(8):1493-1504.
|
|
[26] PONZIANI FR,BHOORI S,CASTELLI C,et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease[J]. Hepatology,2019,69(1):107-120.
|
|
[27] YOSHIMOTO S,LOO TM,ATARASHI K,et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome[J]. Nature,2013,499(7456):97-101.
|
|
[28] LOO TM,KAMACHI F,WATANABE Y,et al. Gut microbiota promotes obesity-associated liver cancer through PGE2-mediated suppression of antitumor immunity[J]. Cancer Discov,2017,7(5):522-538.
|
|
[29] TANOUE T,MORITA S,PLICHTA DR,et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity[J]. Nature,2019,565(7741):600-605.
|
DownLoad: